This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128: 40-50.OgurtsovaKdaRocha Fernandes JDHuangYLinnenkampUGuariguataLChoNHet alIDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 20402017128405010.1016/j.diabres.2017.03.02428437734Search in Google Scholar
International Diabetes Federation. IDF Diabetes Atlas 8th ed., 2017. Brussels, Belgium. (Available at: diabetesatlas.org [accessed: July 15 2018].2017Brussels, BelgiumAvailable athttps://diabetesatlas.org[accessed: July 15 2018]Search in Google Scholar
Hoogwerf BJ, Sferra J, Donley BG. Diabetes mellitus-overview. Foot Ankle Clin. 2006; 11(4): 703-715.HoogwerfBJSferraJDonleyBGDiabetes mellitus-overview200611470371510.1016/j.fcl.2006.06.01417097511Search in Google Scholar
Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016; 20(4): 546-551.ChawlaAChawlaRJaggiSMicrovascular and macrovascular complications in diabetes mellitus: Distinct or continuum?201620454655110.4103/2230-8210.183480491184727366724Search in Google Scholar
Islam T, Rahman MS, Paul N, Akhteruzzaman S, Sajib AA. Allele-specific detection of SLC22A2 rs316019 variants associated with metformin disposition through the kidney. Int J Diabetes and Metab. 2018; 24: 22-28.IslamTRahmanMSPaulNAkhteruzzamanSSajibAAAllele-specific detection of SLC22A2 rs316019 variants associated with metformin disposition through the kidney201824222810.1159/000493584Search in Google Scholar
American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37(Suppl 1): S81-S90.American Diabetes Association (ADA)Diagnosis and classification of diabetes mellitus201437Suppl 1S81S9010.2337/dc14-S08124357215Search in Google Scholar
World Health Organization. WHO model list of essential medicines (20th list) [accessed: October 5 2018].World Health Organization[accessed: October 5 2018]Search in Google Scholar
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: A systematic review. JAMA. 2014; 312(24):2668-2675.InzucchiSELipskaKJMayoHBaileyCJMcGuireDKMetformin in patients with type 2 diabetes and kidney disease: A systematic review2014312242668267510.1001/jama.2014.15298442705325536258Search in Google Scholar
Singh S, Usman K, Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes. 2016; 7(15): 302-315.SinghSUsmanKBanerjeeMPharmacogenetic studies update in type 2 diabetes mellitus201671530231510.4239/wjd.v7.i15.302498063727555891Search in Google Scholar
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577-1596.InzucchiSEBergenstalRMBuseJBDiamantMFerranniniENauckMet alManagement of hyperglycaemia in type 2 diabetes: A patient-centered approach20125561577159610.1007/s00125-012-2534-022526604Search in Google Scholar
Topić E. The role of pharmacogenetics in the treatment of diabetes mellitus. J Med Biochem. 2014; 33(1): 58-70.TopićEThe role of pharmacogenetics in the treatment of diabetes mellitus2014331587010.2478/jomb-2013-0045Search in Google Scholar
Mannino GC, Sesti G. Individualized therapy for type 2 diabetes: Clinical implications of pharmacogenetic data. Mol Diagn Ther. 2012; 16(5): 285-302.ManninoGCSestiGIndividualized therapy for type 2 diabetes: Clinical implications of pharmacogenetic data201216528530210.1007/s40291-012-0002-723018631Search in Google Scholar
Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde, F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study. Diabetes Care. 1994; 17(10): 1100-1109.HermannLSSchersténBBitzénPOKjellströmTLindgärdeFMelanderATherapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study199417101100110910.2337/diacare.17.10.11007821128Search in Google Scholar
Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med. 2007; 24(4): 350-358.CookMNGirmanCJSteinPPAlexanderCMInitial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care200724435035810.1111/j.1464-5491.2007.02078.x17335466Search in Google Scholar
Chen L, Pei JH, Kuang J, Chen HM, Chen Z, Li ZW, et al. Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. Metabolism. 2015; 64(2): 338-347.ChenLPeiJHKuangJChenHMChenZLiZWet alEffect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis201564233834710.1016/j.metabol.2014.10.01825467842Search in Google Scholar
Zia A, Kiani AK, Bhatti A, John P. Genetic susceptibility to type 2 diabetes and implications for therapy. J Diabetes Metab. 2013; 4(3): 248.ZiaAKianiAKBhattiAJohnPGenetic susceptibility to type 2 diabetes and implications for therapy20134324810.4172/2155-6156.1000248Search in Google Scholar
Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009; 86(3): 299-306.TzvetkovMVVormfeldeSVBalenDMeinekeISchmidtTSehrtDet alThe effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin200986329930610.1038/clpt.2009.9219536068Search in Google Scholar
Becker ML, Visser LE, Van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes. 2009; 58(3): 745-749.BeckerMLVisserLEVanSchaik RHNHofmanAUitterlindenAGStrickerBHCGenetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study200958374574910.2337/db08-1028264607519228809Search in Google Scholar
Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 2010; 335(1): 42-50.ChenLTakizawaMChenESchlessingerASegenthelarJChoiJHet alGenetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function20103351425010.1124/jpet.110.170159295778820639304Search in Google Scholar
Sanchez-Ibarra HE, Reyes-Cortes LM, Jiang XL, Luna-Aguirre CM, Aguirre-Trevino D, Morales-Alvarado IA, et al. Genotypic and phenotypic factors influencing drug response in Mexican patients with type 2 diabetes mellitus. Front Pharmacol. 2018; 9: 320.Sanchez-IbarraHEReyes-CortesLMJiangXLLuna-AguirreCMAguirre-TrevinoDMorales-AlvaradoIAet alGenotypic and phenotypic factors influencing drug response in Mexican patients with type 2 diabetes mellitus2018932010.3389/fphar.2018.00320589837229681852Search in Google Scholar
Christensen MMH, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013; 23(10): 526-534.ChristensenMMHPedersenRSStageTBBrasch-AndersenCNielsenFDamkierPet alA gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin2013231052653410.1097/FPC.0b013e328364a57d23873119Search in Google Scholar
Shokri F, Ghaedi H, Fard SG, Movafagh A, Abediankenari S, Mahrooz A, et al. Impact of ATM and SLC22A1 polymorphisms on therapeutic response to met-formin in Iranian diabetic patients. Int J Mol Cell Med. 2016; 5(1): 1-7.ShokriFGhaediHFardSGMovafaghAAbediankenariSMahroozAet alImpact of ATM and SLC22A1 polymorphisms on therapeutic response to met-formin in Iranian diabetic patients20165117Search in Google Scholar
Iskakova AN, Romanova AA, Aitkulova AM, Sikhayeva NS, Zholdybayeva EV, Ramanculov EM. Poly-morphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. BMC Genet. 2016; 17: 23.IskakovaANRomanovaAAAitkulovaAMSikhayevaNSZholdybayevaEVRamanculovEMPoly-morphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan2016172310.1186/s12863-016-0329-x471752826785747Search in Google Scholar
Xhakaza L, Abrahams-October Z, Pearce B, Masilela CM, Adeniyi OV, Johnson R, et al. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metabol Pers Ther. 2020; 35(2): j/ dmdi. 2020.35.issue-2/dmpt-2020-0111/dmpt-2020-0111.xml. doi: 10.1515/dmpt-2020-0111.XhakazaLAbrahams-OctoberZPearceBMasilelaCMAdeniyiOVJohnsonRet alEvaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients2020352j/ dmdi. 2020.35.issue-2/dmpt-2020-0111/dmpt-2020-0111.xml10.1515/dmpt-2020-011132681778Open DOISearch in Google Scholar
Lucassen A, Ehlers K, Grobler P, Shezi AL. Allele frequency data of 14 autosomal STR loci in four major population groups of South Africa. Int J Legal Med. 2018; 128(2): 275-276.LucassenAEhlersKGroblerPSheziALAllele frequency data of 14 autosomal STR loci in four major population groups of South Africa2018128227527610.1007/s00414-013-0898-423892950Search in Google Scholar
Lane AB, Soodyall H, Arndt S, Ratshikhopha ME, Jonker E, Freeman C, et al. Genetic substructure in South African Bantu-speakers: Evidence from auto-somal DNA and Y-chromosome studies. Am J Phys Anthropol. 2002; 119(2): 175-185.LaneABSoodyallHArndtSRatshikhophaMEJonkerEFreemanCet alGenetic substructure in South African Bantu-speakers: Evidence from auto-somal DNA and Y-chromosome studies2002119217518510.1002/ajpa.1009712237937Search in Google Scholar
Xiao D, Zhang S, Li X, Yin J, Gong W, Zheng Y, et al. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese type 2 diabetes mellitus patients. Pharmacogenomics. 2015; 16(14): 1621-1629.XiaoDZhangSLiXYinJGongWZhengYet alIL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese type 2 diabetes mellitus patients201516141621162910.2217/pgs.15.9526401715Search in Google Scholar
Omori S, Tanaka Y, Takahashi A, Hirose H, Kashiwagi A, Kaku K, et al. Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes. 2008; 57(3): 791-795.OmoriSTanakaYTakahashiAHiroseHKashiwagiAKakuKet alAssociation of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population200857379179510.2337/db07-097918162508Search in Google Scholar
Kashki Z, Masoumi P, Mahrooz A, Hashemi-Soteh MB, Bahar A, Alizadeh A. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. Diabetes Res Clin Pract. 2015; 108(1): 78-83.KashkiZMasoumiPMahroozAHashemi-SotehMBBaharAAlizadehAThe variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin20151081788310.1016/j.diabres.2015.01.02425662675Search in Google Scholar
Clinical guidelines (CDE). Available at: http://www.cdediabetes.co.za [accessed: October 30 2018].Available athttp://www.cdediabetes.co.za[accessed: October 302018Search in Google Scholar
Pharmacogenomic knowledge base (PharmGKB). Available at: http://www.pharmgkb.org [accessed: July 5 2018].Available athttp://www.pharmgkb.orgaccessed: July 52018Search in Google Scholar
Leat N, Benjeddou M, Davison S. Nine-locus Y-chromosome STR profiling of Caucasian and Xhosa populations from Cape Town, South Africa. Forensic Sci Int. 2004; 144(1): 73-75.LeatNBenjeddouMDavisonSNine-locus Y-chromosome STR profiling of Caucasian and Xhosa populations from Cape Town, South Africa20041441737510.1016/j.forsciint.2004.02.02215240024Search in Google Scholar
Li T, Xu X, Xu Y, Jin P, Chen J, Shi Y, et al. PPARG Polymorphisms are associated with unexplained mild vision loss in patients with type 2 diabetes mellitus. J Opthalmol. 2019; 2019: 5284867. doi: 10.1155/2019/ 5284867. eCollection 2019.LiTXuXXuYJinPChenJShiYet alPPARG Polymorphisms are associated with unexplained mild vision loss in patients with type 2 diabetes mellitus20192019528486710.1155/2019/5284867. eCollection 2019Open DOISearch in Google Scholar
Jiao X, Yang S, Yang Y, Li J, Sun H, Zhang M, et al. Targeted sequencing analysis of PPARG identifies a risk variant associated with obstructive sleep apnea in Chinese Han subjects. Sleep Breath. 2020; 24(1): 167-174.JiaoXYangSYangYLiJSunHZhangMet alTargeted sequencing analysis of PPARG identifies a risk variant associated with obstructive sleep apnea in Chinese Han subjects202024116717410.1007/s11325-019-01855-x712798931044373Search in Google Scholar
Bhushan B, Guleriab R, Misrac A, Luthrad K, Kumare G. Association of PPARγ2 (Pro12Ala) and neuropeptide Y (Leu7Pro) gene polymorphisms with obstructive sleep apnea in obese Asian Indians. Dis Markers. 2011; 30(1): 31-38.BhushanBGuleriabRMisracALuthradKKumareGAssociation of PPARγ2 (Pro12Ala) and neuropeptide Y (Leu7Pro) gene polymorphisms with obstructive sleep apnea in obese Asian Indians2011301313810.1155/2011/410397Search in Google Scholar
Zhou J-X, Li H-C, Bai X-J, Chang B-C, Li C-J, Sun P, et al. Functional Val66Met polymorphism of brain-derived neurotrophic factor in type 2 diabetes with depression in Han Chinese subjects. Behav Brain Funct. 2013; 9: 34.ZhouJ-XLiH-CBaiX-JChangB-CLiC-JSunPet alFunctional Val66Met polymorphism of brain-derived neurotrophic factor in type 2 diabetes with depression in Han Chinese subjects201393410.1186/1744-9081-9-34376587023968401Search in Google Scholar
Wu L, Xi B, Zhang M, Shen Y, Zhao X, Cheng H, et al. Associations of six single nucleotide polymorphisms in obesity related genes with BMI and risk of obesity in Chinese children. Diabetes. 2010; 59(12): 3085-3089.WuLXiBZhangMShenYZhaoXChengHet alAssociations of six single nucleotide polymorphisms in obesity related genes with BMI and risk of obesity in Chinese children201059123085308910.2337/db10-0273299276920843981Search in Google Scholar
Hong K, Lim J, Go M, Cho Y, Ahn Y, Han B, et al. Recapitulation of the association of Val66Met polymorphism of BDNF gene with BMI in Koreans. Obesity. 2012; 20(9): 1871-1875.HongKLimJGoMChoYAhnYHanBet alRecapitulation of the association of Val66Met polymorphism of BDNF gene with BMI in Koreans20122091871187510.1038/oby.2011.35222173577Search in Google Scholar
Shugart Y, Chen L, Day I, Lewis S, Timpson S, Yuan W, et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet. 2009; 17(8): 1050-1055.ShugartYChenLDayILewisSTimpsonSYuanWet alTwo British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI20091781050105510.1038/ejhg.2008.272298656019209189Search in Google Scholar
Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009; 19(7): 497-504.ChenYLiSBrownCCheathamSCastroRALeabmanMKet alEffect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin200919749750410.1097/FPC.0b013e32832cc7e9310449619483665Search in Google Scholar
Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, et al. A longitudinal HbA1c model elucidates genes linked to disease progression on met-formin. Clin Pharmacol Ther. 2016; 100(5): 537-547.GoswamiSYeeSWXuFSridharSBMosleyJDTakahashiAet alA longitudinal HbA1c model elucidates genes linked to disease progression on met-formin2016100553754710.1002/cpt.428553424127415606Search in Google Scholar
Wang ZJ, Yin OQP, Tomlinson B, Chow MSS. OCT2 Polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet Genomics. 2008; 18(7): 637-645.WangZJYinOQPTomlinsonBChowMSSOCT2 Polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine200818763764510.1097/FPC.0b013e328302cd4118551044Search in Google Scholar
Sajib AA, Islam T, Paul N, Yeasmin S. Interaction of rs316019 variants of SLC22A2 with metformin and other drugs-an in silico analysis. J Genet Eng Biotechnol. 2018; 16(2): 769-775.SajibAAIslamTPaulNYeasminSInteraction of rs316019 variants of SLC22A2 with metformin and other drugs-an in silico analysis201816276977510.1016/j.jgeb.2018.01.003635365430733798Search in Google Scholar
Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Phar-macol Ther. 2008; 84(5):559-562.SongISShinHJShimEJJungISKimWYShonJHet alGenetic variants of the organic cation transporter 2 influence the disposition of metformin200884555956210.1038/clpt.2008.6118401339Search in Google Scholar
Zolk O, Solbach TF, König J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009; 37(6): 1312-1318.ZolkOSolbachTFKönigJ,FrommMFFunctional characterization of the human organic cation transporter 2 variant p.270Ala>Ser20093761312131810.1124/dmd.108.02376219251820Search in Google Scholar
Tkac I, Javorsky M, Klimcakova L, Zidzik J, Gala I, Babjakova E, et al. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. Eur J Clin Pharmacol. 2015; 71(1): 59-63.TkacIJavorskyMKlimcakovaLZidzikJGalaIBabjakovaEet alA pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes2015711596310.1007/s00228-014-1774-y25327507Search in Google Scholar
Chung J-Y, Cho SK, Kim TH, Kim KH, Jang GH, Kim CO, et al. Functional characterization of MATE2-K genetic variants and their effcts on met-formin pharmacokinetics. Pharmacogenet Genomics. 2013; 23(7): 365-373.ChungJ-YChoSKKimTHKimKHJangGHKimCOet alFunctional characterization of MATE2-K genetic variants and their effcts on met-formin pharmacokinetics201323736537310.1097/FPC.0b013e328362203723652408Search in Google Scholar
Speidel JT, Xu M, Abdel-Rahman SZ. Promoter haplotypes of the ABCB1 gene encoding the p-glycoprotein differentially affect its promoter cctivity by altering transcription factor binding. DNA Cell Biol. 2018; 37(12): 973-981.SpeidelJTXuMAbdel-RahmanSZPromoter haplotypes of the ABCB1 gene encoding the p-glycoprotein differentially affect its promoter cctivity by altering transcription factor binding2018371297398110.1089/dna.2018.4376630281530277801Search in Google Scholar